A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) Versus Crizotinib in Patients With ALK-positive Advanced Lung Cancer

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 06 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brigatinib (Primary) ; Crizotinib
Indications Adenocarcinoma; Large cell carcinoma; Non-small cell lung cancer; Squamous cell cancer
Focus Registrational; Therapeutic Use
Acronyms ALTA 1L
Sponsors ARIAD Pharmaceuticals

12 Sep 2023 Results (n=34 from studies NCT03707938 and NCT02737501) assessing retrospective comparison of Disease burden by overall 3D tumor volume presented at the 24th World Conference on Lung Cancer
06 Jun 2023 Results of pooled analysis from ALTA-1L and J-ALTA , presented at the 59th Annual Meeting of the American Society of Clinical Oncology
13 Sep 2022 Results assessing treatment differences on the quality of survival of brigatinib versus crizotinib in ALK-positive non-small cell lung cancer patients, presented at the 47th European Society for Medical Oncology Congress.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com